Repligen (NASDAQ:RGEN) Upgraded at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a report issued on Friday morning.

Other equities research analysts also recently issued reports about the company. Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price on the stock. TD Cowen began coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.64.

Repligen Stock Down 8.0 %

Shares of RGEN opened at $111.94 on Friday. The business’s 50 day moving average is $150.03 and its 200 day moving average is $147.62. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $106.78 and a 12-month high of $182.52. The company has a market capitalization of $6.29 billion, a PE ratio of -219.49, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Research analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently bought and sold shares of RGEN. Ballentine Partners LLC grew its holdings in shares of Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 72 shares during the last quarter. CIBC Asset Management Inc boosted its position in Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 81 shares during the period. MML Investors Services LLC grew its stake in Repligen by 2.7% in the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after acquiring an additional 89 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Repligen by 15.2% during the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System raised its stake in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.